PX’Therapeutics and Intervacc

to collaborate for the development of Strangvac®

Grenoble (France), January 20th, 2016

PX’Therapeutics SAS, a CDMO (Contract Development and Manufacturing Organization) subsidiary of Aguettant pharmaceutical group, has signed an agreement with Intervacc AB, a Swedish company focused on the new generation of recombinant vaccines within animal health. With a strong expertise in recombinant proteins and with capacities for bioproduction, PX’Therapeutics will be in charge of process transfer and optimization as well as GMP manufacturing of Strangvac®.

This vaccine against strangles is made of a number of recombinant proteins, both from the surface of Streptococcus equi and secreted proteins involved in immune evasion. Strangvac® is currently used in confirmatory pivotal trials in compliance with GCP (Good Clinical Practice), which will be part of a dossier for a market authorization application. These studies will confirm efficacy, duration of protective immunity and the effect of re-vaccination.